We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
From Apr 2019 to Apr 2024
By Chris Wack
ALX Oncology Holdings Inc. said Tuesday it is collaborating with Merck & Co. to evaluate the combination of ALX148 and Keytruda for treating patients with a certain type of head and neck cancer.
Under the terms of the agreement, ALX Oncology will conduct two Phase 2 studies. The first will evaluate the efficacy of ALX148, an investigational next generation CD47 blocker, in combination with Merck's drug to treat patients with PD-L1 expressing metastatic or unresectable, recurrent head and neck squamous cell carcinoma.
The second study will evaluate ALX148, Keytruda and standard chemotherapy to treat patients with metastatic or unresectable, recurrent HNSCC.
ALX Oncology owns worldwide commercial rights to ALX148.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 22, 2020 07:51 ET (11:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
